Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Internal Medicine Neurology Oncology Pediatrics Respiratory Medicine Surgery
Congress Coverage
2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting

Keynote Webinar | Spotlight on Diet and Diabetes

Watch on-demand

An expert-led symposium exploring the prevention and management of type 2 diabetes through dietary interventions. 
ADVANCED SEARCH
Log in
Top
Cellular Oncology

20-11-2023 | Glioblastoma | Research

CHIP promotes CAD ubiquitination and degradation to suppress the proliferation and colony formation of glioblastoma cells

Authors: Guanya Li, Kai Xiao, Yinan Li, Jianfang Gao, Shanping He, Tingting Li

Published in: Cellular Oncology

Login to get access

Abstract

Purpose

Cancer cells are characterized as the uncontrolled proliferation, which demands high levels of nucleotides that are building blocks for DNA synthesis and replication. CAD (carbamoyl-phosphate synthetase 2, aspartate transcarbamylase and dihydroorotase) is a trifunctional enzyme that initiates the de novo pyrimidine synthesis, which is normally enhanced in cancer cells to preserve the pyrimidine pool for cell division. Glioma, representing most brain cancer, is highly addicted to nucleotides like pyrimidine to sustain the abnormal growth and proliferation of cells. CAD is previously reported to be dysregulated in glioma, but the underlying mechanism remains unclear.

Methods

The expression of CAD and CHIP (carboxyl terminus of Hsc70-interacting protein) protein in normal brain cells and three glioblastoma (GBM) cell lines were measured by immunoblots. Lentiviruses-mediated expression of target proteins or shRNAs were used to specifically overexpress or knock down CAD and CHIP. Cell counting, colony formation, apoptosis and cell cycle assays were used to assess the roles of CAD and CHIP in GBM cell proliferation and survival. Co-immunoprecipitation and ubiquitination assays were used to examine the interaction of CHIP with CAD and the ubiquitination of CAD. The correlation of CAD and CHIP expression with GBM patients’ survival was obtained by analyzing the GlioVis database.

Results

In this study, we showed that the expression of CAD was upregulated in glioma, which was positively correlated with the tumor grade and survival of glioma patients. Knockdown of CAD robustly inhibited the cell proliferation and colony formation of GBM cells, indicating the essential role of CAD in the pathogenesis of GBM. Mechanistically, we firstly identified that CAD was modified by the K29-linked polyubiquitination, which was mediated by the E3 ubiquitin ligase CHIP. By interacting with and ubiquitinating CAD, CHIP enhanced its proteasomal and lysosomal degradation, which accounted for the anti-proliferative role of CHIP in GBM cells. To sustain the expression of CAD, CHIP is significantly downregulated, which is correlated with the poor prognosis and survival of GBM patients. Notably, the low level of CHIP and high level of CAD overall predict the short survival of GBM patients.

Conclusion

Altogether, these results illustrated the essential role of CAD in GBM and revealed a novel therapeutic strategy for CAD-positive and CHIP-negative cancer.
Literature
1.
2.
3.
H.S. Phillips et al., Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of Disease progression, and resemble stages in neurogenesis. Cancer Cell. 9(3), 157–173 (2006) PubMedCrossRef
4.
R. Stupp et al., Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10(5), 459–466 (2009) PubMedCrossRef
5.
B. Faubert, A. Solmonson, R.J. DeBerardinis, Metabolic reprogramming and cancer progression. Science. 368(6487), 152– (2020) CrossRef
6.
I. Martinez-Reyes, N.S. Chandel, Cancer metabolism: looking forward. Nat. Rev. Cancer. 21(10), 669–680 (2021) PubMedCrossRef
7.
8.
G. Li et al., Pyrimidine biosynthetic enzyme CAD: its function, regulation, and diagnostic potential. Int. J. Mol. Sci., 22(19), 10253 (2021)
9.
J. Shin et al., Allosteric regulation of CAD modulates de novo pyrimidine synthesis during the cell cycle. Nat. Metabolism. 5(2), 277– (2023) CrossRef
10.
J.A. Cox et al., Novel role for carbamoyl phosphate synthetase 2 in cranial sensory circuit formation. Int. J. Dev. Neurosci. 33, 41–48 (2014) PubMedCrossRef
11.
D.A. Ridder et al., Key enzymes in Pyrimidine Synthesis, CAD and CPS1, predict prognosis in Hepatocellular Carcinoma. Cancers (Basel), 13(4), 744 (2021)
12.
R.J. Miltenberger, K.A. Sukow, P.J. Farnham, An e-box-mediated increase in cad transcription at the G1/S-phase boundary is suppressed by inhibitory c-Myc mutants. Mol. Cell. Biol. 15(5), 2527–2535 (1995) PubMedPubMedCentralCrossRef
13.
14.
L. Lee et al., Oligomeric structure of the multifunctional protein CAD that initiates pyrimidine biosynthesis in mammalian cells. Proc. Natl. Acad. Sci. U S A 82(20), 6802–6806 (1985) PubMedPubMedCentralCrossRef
15.
M. Moreno-Morcillo et al., Structural insight into the core of CAD, the multifunctional protein leading De Novo Pyrimidine Biosynthesis. Structure. 25(6), 912– (2017) PubMedCrossRef
16.
I. Ben-Sahra et al., Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science 339(6125), 1323-1328 (2013)
17.
D.H. Kotsis et al., Protein kinase a phosphorylation of the multifunctional protein CAD antagonizes activation by the MAP kinase cascade. Mol. Cell. Biochem. 301(1–2), 69–81 (2007) PubMedCrossRef
18.
L.M. Graves et al., Regulation of carbamoyl phosphate synthetase by MAP kinase. Nature. 403(6767), 328–332 (2000) PubMedCrossRef
19.
20.
C.A. Ballinger et al., Identification of CHIP, a Novel Tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol. Cell Biol. 19(6), 4535–4545 (1999)
21.
22.
S.M. Ronnebaum et al., The ubiquitin ligase CHIP prevents SirT6 degradation through noncanonical ubiquitination. Mol. Cell. Biol. 33(22), 4461–4472 (2013) PubMedPubMedCentralCrossRef
23.
Y. Kopp et al., CHIP as a membrane-shuttling proteostasis sensor. Elife, 6, e29388 (2017)
24.
S.F. Ahmed et al., The chaperone-assisted E3 ligase C terminus of Hsc70-interacting protein (CHIP) targets PTEN for proteasomal degradation. J. Biol. Chem. 287(19), 15996–16006 (2012) PubMedPubMedCentralCrossRef
25.
M.M. Al Mamun et al., Stub1 maintains proteostasis of master transcription factors in embryonic stem cells. Cell Rep., 39(10), 110919 (2022)
26.
C.F. Liu et al., Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced Prostate cancer. Nat. Commun., 9(1), 4700 (2018)
27.
I. Paul et al., The ubiquitin ligase CHIP regulates c-Myc stability and transcriptional activity. Oncogene. 32(10), 1284–1295 (2013) PubMedCrossRef
28.
M. Kajiro et al., The ubiquitin ligase CHIP acts as an upstream regulator of oncogenic pathways. Nat. Cell Biol. 11(3), 312–U190 (2009) PubMedCrossRef
29.
G. Zhao et al., DDX39B drives Colorectal cancer progression by promoting the stability and nuclear translocation of PKM2. Signal Transduct. Target. Therapy, 7(1), 275 (2022)
30.
T. Xu et al., Carboxyl terminus of Hsp70-interacting protein (CHIP) contributes to human glioma oncogenesis. Cancer Sci. 102(5), 959–966 (2011) PubMedCrossRef
31.
J. Hou et al., CSN6 controls the proliferation and Metastasis of glioblastoma by CHIP-mediated degradation of EGFR. Oncogene. 36(8), 1134–1144 (2017) PubMedCrossRef
32.
H.R. Ko et al., P42 Ebp1 regulates the proteasomal degradation of the p85 regulatory subunit of PI3K by recruiting a chaperone-E3 ligase complex HSP70/CHIP. Cell. Death Dis. 5(3), e1131 (2014) PubMedPubMedCentralCrossRef
33.
L.W. Sun et al., Corosolic acid attenuates the invasiveness of Glioblastoma Cells by promoting CHIP-Mediated AXL degradation and inhibiting GAS6/AXL/JAK Axis. Cells, 10(11), 2919 (2021)
34.
T. Li, E. Ju, S.J. Gao, Kaposi sarcoma-associated herpesvirus miRNAs suppress CASTOR1-mediated mTORC1 inhibition to promote tumorigenesis. J. Clin. Invest. 129(8), 3310–3323 (2019) PubMedPubMedCentralCrossRef
35.
T.Y. Wang et al., The E3 Ubiquitin Ligase CHIP in Normal cell Function and in Disease Conditions, Ann N Y Acad Sci. 1460(1), 3-10 (2020)
36.
K. Radovanac et al., Stabilization of integrin-linked kinase by the Hsp90-CHIP axis impacts cellular force generation, migration and the fibrotic response. EMBO J. 32(10), 1409–1424 (2013) PubMedPubMedCentralCrossRef
37.
38.
I. Dikic, B.A. Schulman, An expanded lexicon for the ubiquitin code. Nat. Rev. Mol. Cell Biol. 24(4), 273–287 (2023) PubMedCrossRef
39.
T. Li et al., RNF167 activates mTORC1 and promotes tumorigenesis by targeting CASTOR1 for ubiquitination and degradation. Nat. Commun. 12(1), 1055 (2021) PubMedPubMedCentralCrossRef
40.
41.
T.P. Mathews et al., Human phospholipase D activity transiently regulates pyrimidine biosynthesis in malignant gliomas. ACS Chem. Biol. 10(5), 1258–1268 (2015) PubMedPubMedCentralCrossRef
42.
43.
G.R. Buel, S.G. Kim, J. Blenis, mTORC1 signaling Aids in CADalyzing pyrimidine biosynthesis. Cell. Metab. 17(5), 633–635 (2013) PubMedCrossRef
44.
L. Petrucelli et al., CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet. 13(7), 703–714 (2004) PubMedCrossRef
45.
P. Connell et al., The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat. Cell. Biol. 3(1), 93–96 (2001) PubMedCrossRef
46.
X. Zhu et al., Ubiquitination of inositol-requiring enzyme 1 (IRE1) by the E3 ligase CHIP mediates the IRE1/TRAF2/JNK pathway. J. Biol. Chem. 289(44), 30567–30577 (2014) PubMedPubMedCentralCrossRef
47.
M. Yang et al., E3 ubiquitin ligase CHIP facilitates toll-like receptor signaling by recruiting and polyubiquitinating src and atypical PKC{zeta}. J. Exp. Med. 208(10), 2099–2112 (2011) PubMedPubMedCentralCrossRef
48.
49.
S. Wang et al., CHIP functions as a novel suppressor of tumour angiogenesis with prognostic significance in human gastric cancer. Gut. 62(4), 496–508 (2013) PubMedCrossRef
50.
J. Xu et al., E3 ubiquitin ligase CHIP attenuates cellular proliferation and invasion abilities in triple-negative Breast cancer cells. Clin. Exp. Med. 20(1), 109–119 (2020) PubMedCrossRef
51.
K. Pan et al., STUB1-SMYD2 Axis regulates Drug Resistance in Glioma cells. J. Mol. Neurosci. 72(9), 2030–2044 (2022) PubMedCrossRef
Metadata
Title
CHIP promotes CAD ubiquitination and degradation to suppress the proliferation and colony formation of glioblastoma cells
Authors
Guanya Li
Kai Xiao
Yinan Li
Jianfang Gao
Shanping He
Tingting Li
Publication date
20-11-2023
Publisher
Springer Netherlands
Published in
Cellular Oncology
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-023-00899-2

European Society for Medical Oncology Congress 2023

NSCLC Video

ESMO23: Non-small-cell lung cancer highlights

Watch the panel discussion

Dr. Luis Paz-Ares, Prof. Solange Peters and Dr. Marina Garassino provide their insights on the latest findings from the following pivotal phase III trials: ALINA, CheckMate-77T, LIBRETTO-431, and MARIPOSA-1 and -2.

Supported by: F. Hoffmann-La Roche Ltd.
Dr. Luis Paz-Ares
Prof. Solange Peters
Dr. Marina Garassino

ESMO23: Small-cell lung cancer highlights

SCLC Expert Interview

Cancer of Unknown Primary: Key results from ESMO 2023

Cancer of Unknown Primary Expert Interview

Tisotumab vedotin improves recurrent and metastatic cervical cancer survival

25-10-2023 Cervical Cancer News

EV-302 heralds practice change for advanced urothelial cancer

24-10-2023 Urothelial Cancer News

First-line selpercatinib supported for RET-mutant medullary thyroid cancer

23-10-2023 Thyroid Cancer News

» View more highlights on the ESMO 2023 hub page

Test your knowledge with Case-Based Clinical Insights

Oncology and Hematology Cases

45/♀ with increasing weakness, loss of appetite, diarrhoea and oedema – Case 29

Case-Based Insights: Oncology and Hematology Training Course

A 45-year-old female patient complains that she has been getting weaker and weaker for several months. She has no appetite and suffers from diarrhoea. Immunofixation shows monoclonal lambda light chains in the serum. What is your tentative diagnosis?

48/♀ with increasing spontaneous haematomas all over her body – Case 37

Case-Based Insights: Oncology and Hematology Training Course

A 48-year-old female patient feels listless and reports petechiae occurred for the first time. In the last 3 days, she had reportedly developed severe toothache and fever. The blood count shows severe pancytopenia. What are your first steps?

49/♀ with lymphoedema of the arm in condition of metastasised triple-negative breast carcinoma – Case 43

Case-Based Insights: Oncology and Hematology Training Course

The 49-year-old female patient presents with significant swelling of the right arm. She reports having been diagnosed with breast cancer 1½ years ago, followed by surgical removal of the tumour. She had then received chemotherapy and irradiation. How do you proceed?

53/♂ with movement-dependent pain in the left anterior pelvis and bloody urine – Case 39

Case-Based Insights: Oncology and Hematology Training Course

A 53-year-old man complains of increasing pain in the left anterior pelvis, which is described as movement-dependent with radiation into the left lower extremity. For several months, he had noticed bloody urine from time to time without pain during micturition. What are your suspicions?

Image Credits